Dechra Pharmaceuticals (DPH)

 

DPH Share PerformanceMore

52 week high1,970.0 02/06/17
52 week low1,225.0 09/12/16
52 week change 433.0 (33.41%)
4 week volume3,191,186 30/06/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 0613M Dechra Pharmaceuticals PLC 25 July 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Dechra Ph...

Dechra growth driven by core portfolio

Dechra Pharmaceuticals said trading in the year ended 30 June was strong and in line with management expectations, with...

Trading Update & Notice of Annual Results

RNS Number: 2572K Dechra Pharmaceuticals PLC 06 July 2017 Thursday 6 July 2017 Dechra Pharmaceuticals PLC (Dechra, Group or Company) Trading Update The Board of Dechra issues the following unaudited Trading Update for the Group's financial year ended 30 June 2017 (Period) ahead of its preliminary financial results which will be announced on Mon...

Total Voting Rights

RNS Number: 7313J Dechra Pharmaceuticals PLC 30 June 2017 30 June 2017 Dechra Pharmaceuticals PLC (Dechra or the Company) Total Voting Rights In conformity with DTR 5.6.1R, the Company notifies the market of the following: As at the date of this announcement, the Company's issued share capital consists of 93,178,756 ordinary shares with a nominal value ...

Director Deals - Dechra Pharmaceuticals PLC (DPH)

Ian Page, Chief Executive Officer, sold 134,500 shares in the company on the 21st June 2017 at a price of 1927.00p. The Direc...

Director/PDMR Shareholding

RNS Number: 8577I Dechra Pharmaceuticals PLC 22 June 2017 22 June 2017 Dechra Pharmaceuticals PLC Notification of Transactions by Persons Discharging Managerial Responsibilities Dechra Pharmaceuticals PLC has been notified that on 21 June 2017 Ian Page, Director, sold 134,500 ordinary shares in the Company at a price of 19.27 each. Following this disposal I...

Total Voting Rights

RNS Number: 7412G Dechra Pharmaceuticals PLC 31 May 2017 31 May 2017 Dechra Pharmaceuticals PLC (Dechra or the Company) Total Voting Rights In conformity with DTR 5.6.1R, the Company notifies the market of the following: As at the date of this announcement, the Company's issued share capital consists of 93,175,657 ordinary shares with a nominal value ...

Holding(s) in Company

RNS Number: 5577F Dechra Pharmaceuticals PLC 18 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii DECHRA PHARMACEUTICALS PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal o...

Fundamental DataMore

P/E ratio123.5
EPS14
Dividend yield1.068 %

Equity Research (DPH)

edison investment research
Dechra Pharmaceuticals plc
10/09/2015
Dechra Pharmaceuticals delivered FY15 revenue growth of 10% CER to £203.5m and EPS growth of 16.9% from 36.3p to 39.9p, with strong sales performances in its Companion Animal Products (CAP) segment,...
edison investment research
Dechra Pharmaceuticals plc
08/07/2015
Dechra Pharmaceuticals’ medium-term outlook is underpinned by a sharpened portfolio focus, new product launches and geographic expansion. Solid performances on these fronts in FY15 have overcome the...
edison investment research
Dechra Pharmaceuticals plc
29/04/2015
Dechra Pharmaceuticals has delivered another solid quarter with revenue growth up 6.0% (14.3% CER), resulting in nine-month growth of 6.6% (12.3% CER). Although boosted by phasing of pre-Easter...

Latest discussion posts More

  • Re: Overvalued?

    Hi Pharma Do you have a reference / weblink for the future earnings forecasts? I only ask as I've had a look through the recent results and last year's annual report and ...
    17-May-2017
    robmonster
  • Re: Overvalued?

    In actual fact the p/e of Dechra seems so high because it is based on the most recent annual earnings. If you base it on next years earnings it comes down to just under 30 and ...
    16-May-2017
    pharmaspecialist
  • Re: Overvalued?

    Valeite, "Lloyds have been added to the CF Woodford Income fund" That fact alone should be enough to warn one off Lloyds LOL. I shall stick with Dechra notwithstanding ...
    16-May-2017
    LK Hyman

Users' HoldingsMore

Users who hold Dechra Pharmaceuticals also hold..
NATIONAL GRID43%
DIAGEO37%
LLOYDS GRP.30%
PZ CUSSONS24%
SHIRE23%

Codes & Symbols

ISINGB0009633180
SymbolsDPH, LSE:DPH, DPH.L, DPH:LN, LON:DPH, XLON:DPH